Immunotherapy for Inhalant Allergy
Introduction
Introduction
- Allergic rhinitis (AR) and allergic asthma (AA) are caused by an immunoglobulin E (IgE) mediated inflammatory response to proteins (or glycoproteins) carried by inhaled organic particles such as pollen, animal dander, mold spores, and/or mite/insect debris.
- Inhalant allergies can be treated by immunotherapy, pharmaceuticals, or by reducing environmental exposure to the allergen.
- Inhalant allergen immunotherapy (AIT) is administered to millions of patients for AR and AA and is most commonly delivered as subcutaneous immunotherapy (SCIT) or sublingual immunotherapy (SLIT).
- Variability in the initiation and delivery of safe and effective immunotherapy provides opportunities for evidence-based recommendations to improve patient care.
Treatment
...eatment...
.... Abbreviations and Definitions of Comm...
...ary of Guideline Key Action Stateme...
...sessment...
...for Allergen ImmunotherapyClinicians...
...should not get Allergen ImmunotherapyCl...
...not get Allergen ImmunotherapyClinic...
...a AssessmentClinicians should evaluate the patie...
...cation...
...Education regarding SLIT versus SC...
...regarding Preventive Qualities of Allergen...
Treatment
...sonal TherapyClinicians who admini...
...g Clinically Relevant AllergensClini...
...lysensitized Patients with Limited Allerg...
...ons and Allergen Immunotherapy EscalationClin...
...0. Anaphylaxis Identification and Managemen...
11. Retesting During Allergen Immunotherapy...
...for Allergen ImmunotherapyFor patients...
...arison of SCIT and SLIT Modalities o...
...le 4. World Allergy Organization Subcutaneous Im...
...1. Pre-/Co-Seasonal SLIT Time CourseTime...
...e 2. Anaphylaxis Diagnostic Criteria Reprod...
Table 5. Differentiating Between Vaso...
...anagement of AnaphylaxisReproduced fr...
...e 4. Flowchart Showing Key Action Statements an...